http://www.envita.com/conditions-we-treat/cancer/stage-4cancer/ - Stage 4 Cancer is also known as Stage IV Cancer, which spread to various sites in the body. It is a complex type of cancer to treat, and it can involve many organ systems.
1. Key Techniques for Stage 4 Cancer
Research on angiogenesis and stage 4 cancer– the method by which tumors attract
blood vessels to nourish themselves was begun by Dr. Judah Folkman, who determined
that a tumor placed in a lab container had a limited potential for growth. Moreover, he
established that the micro vascular network for the cancer could be disrupted.
Like so many great scientific minds with a new idea, Folkman was often ignored by his
colleagues and peers for 20 or more of his original findings. While it should be said that
many agreed there was evidence of newly formed vessels – the dissenting assumption
was that the detected inferior cell networks were merely a byproduct of dying tumor
cells. Some years later Folkman could prove that they, in fact, being created by the
cancer cells as a means to deliver them their much needed nutrients. Folkman's
findings are critical for all cancer patients and stage 4 cancer patients as you will see.
Now consider this for a moment. The United States Government website
HealthReport.gov contends that, “Nearly one out of two Americans born today will be
diagnosed with cancer at some point in their lifetime. About 1,596,670 new cancer,
cases are expected to be diagnosed in 2011 – and about 571,950 Americans are
expected to die of cancer, more than 1,500 people a day – and cancer is the second
most common cause of death in the US, exceeded only by heart disease. In the US,
cancer alone accounts for nearly 1 of every 4 deaths."
With such a destructive epidemic facing us, one would think that new ideas and
innovation would be welcomed with open arms. Nevertheless, we regularly and have
even come to expect the all-to-familiar pattern of contempt for ground-breaking
innovators and thinkers.
In another example, devoted researcher Dr. Don Ingber was studying endothelial cells
when one of his test samples became contaminated with a fungus. He was amazed to
see that in the presence of this fungus, the cells actually stopped growing. As fate
2. would have it, Ingber’s original position that angiogenesis could be inhibited was
ultimately supported. Today anti-angiogenic drugs are a multibillion-dollar
pharmaceutical industry and doctors like Folkan and Ingber, should receive far greater
commendation for their works – rather than the usual condemnation.
Anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib
(Votrient®), and everolimus (Afinitor®) are typically prescribed in late-stage cancers in
order to slow growth. However, a simple agent like oxygen (non patentable) is an often
overlooked for the dominant anti-angiogenic agent that it is. In fact, oxygen metabolism
errors are involved in the cause and development of many cancers. These strategies
culminate with more than a decade of combining conventional and advanced natural
approaches to treat cancer. Understanding the role of oxygen and using is correctly is
vital for success, particularly when treating stage 4 cancer.
In light of such grim aforementioned statistics, it is imperative that we must work
collectively and with open minds to defeat the venerable adversary called cancer,
especially stage 4 cancer.
Through all the struggles, some bright lights have emerged – and perhaps this one has
its place among the brightest - anti-angiogenic therapy. In simple terms, it is designed to
starve stage 4 cancers from much-needed nutrients thereby blocking its development,
growth, and spread.
This is revolutionary when one considers that 90 percent of cancer patients succumb to
their disease because their cancer has spread beyond its original site (metasized) – the
picture of stage 4 cancer diagnosis. The fact that we may now inhibit tumor
angiogenesis – is a quantum leap for treatment protocols.
While such treatments are viewed as being in their fledgling states by conventional
institutions, Envita has already realized stunning success with them. In fact, it has been
found that integrating these anti-angiogenic methods with traditional chemotherapy and
radiation can work synergistically with the body and produce impressive results.
Because of the incredible threat, it imposes, there is no question that angiogenesis
should be blocked to stop tumor growth. In fact, without it, tumor growth is limited to a
miniscule 2 mm in size. Envita’s specifically designed cancer therapies work by shutting
off nutrients to the tumors and ultimately destroy the cancer cells that rely on them.
In addition to this approach, a protein known as VEGF (*vascular endothelial growth
factor) has been identified as the agent that stimulates angiogenesis. It has been found
that a tumor releases VEGF for a variety of factors - one of which is triggered by a lack
of oxygen, or hypoxia. This process is brought into being by the transcriptional factor
HIF-1 (hypoxia inducible factor 1).
One thing we can count on is that a tumor will always attempt to grow, even beyond the
support of its existing blood supplies. As a result, there is always a need for hypoxic
tissue on the tumor so it can create more VEGF. That alone is enough to suggest to
Envita that correcting a tumor’s oxygen metabolism will likely yield positive results.
3. You see, without VEGF tumors simply cannot grow or spread. By introducing reactive
oxygen species, it is possible to potentiate other cancer treatments as they stimulate a
change from anaerobic to aerobic that a tumor, by nature, will detest. Creating an
environment that naturally repels stage 4 cancer is a critical method by which to
facilitate and maintain remission.
But how can this be done effectively?
Well, VEGF has been shown to bind to certain cells, called endothelials, of the nearby
blood vessels. These cells diverge and grow in the direction of the tumor forming new,
albeit inferior blood vessels that actually rely on VEGF to survive. As fate would have it,
they are not as difficult as one might think to detect. So, the goal then becomes
targeting and destroying these rogue vessels while bolstering healthy ones. The end
result accelerates energy, cardiovascular stamina, and the patient’s overall endurance.
It has been determined that VEGF is connected to a broad series of tumor types,
including breast, ovarian, cervical, esophageal, lung, and cervical cancer, as well as
glioblastoma multiforme and renal cell carcinoma. It would seem that VEGF emissions
may also hinder the immune system’s ability to react and fight off the tumor - regularly
occurring in stage 4 cancers.
Remember, the immune system is our first and last defense against stage 4 cancer.
While many patients believe that their cancer has been destroyed, they often find out
that dormant metastasis was biding its time to strike. We can, however, attempt to
thwart its efforts by correcting the body’s oxygen metabolism – thereby stopping
angiogenesis in its tracks.
If you know anyone who has been diagnosed with cancer or stage 4 cancer, please
forward this article to them. We at Envita welcome you to contact us with questions and
invite you to watch our informative videos. You can also visit our PPMR section to learn
more about the power of our personalized medicine for cancer and chronic diseases. It
is important information that may save lives. Education is the best prescription.
Take advantage of Envita’s Comprehensive Smart Oncology (link to Envita cancer),
which incorporates the foremost treatment approaches and synchronizes them with
aggressive natural therapies to help each patient far greater results.
References:
*Judah Folkman <http://www.pbs.org/wgbh/nova/body/cancer-warrior.html > , <
http://en.wikipedia.org/wiki/Judah_Folkman > *Stage 4 Cancer <
http://en.wikipedia.org/wiki/Stage-4_cancer#Systems_of_staging > * Vascular
endothelial growth factor
<http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor>*HealthReform.gov
<http://www.healthreform.gov/reports/fightingcancer/index.html>*American Cancer
Society
